Business briefs Merck/Cerecor, Alcon, Eli Lilly

Share this article:

Biotech Cerecor has acquired rights and licensing from Merck to develop and market COMT inhibitors—a potential treatment for Parkinson's. COMT is an enzyme that breaks down dopamine, and drugs that block COMT have been used to treat Parkinson's disease. Cerecor also noted that its possible COMT inhibitors could be used to treat other neurological disorders like schizophrenia and addiction. The Baltimore-based biotech will review more than 2,000 potential drugs for clinical development. Merck may receive milestone payments and some royalties from sales of any drugs that are approved. Specifics of the deal were not disclosed.

Alcon launched DROPS101, an educational mobile website, today. The platform is designed to help parents find prescription savings info, dosing instructions, and games to reward children for adherence and occupy them during drop administration. It's all bundled into a social media sharing platform. Alcon marketing manager, Amt Patyk, said in the release: “We heard from patients that they needed a one-click resource for prescribed eye and ear treatments. When we developed DROPS101, our goal was to improve communication between healthcare professionals and patients.”

Two out of three people were unfamiliar with personalized medicine according to a study commissioned by Eli Lilly and conducted by Gfk. While a third weren't aware of the phenomenon, the majority “were supportive once the concept was introduced,” researchers said, and 72% didn't believe “there was enough information available to patients about new treatment options like personalized medicine.” The findings were presented at the European Alliance for Personalized Medicine; the survey polled 4,341 individuals, of which 3,009 were general population and 663 were cancer patients.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.